Dermatologist-Approved Remedies for Chronic Spontaneous Urticaria (CSU)

Chronic spontaneous urticaria (CSU), commonly known as chronic hives, is a persistent skin condition marked by itchy, red welts that can last for months or even years. While there is no cure, dermatologist-approved treatments—including emerging therapies like dupilumab—can help manage symptoms and improve quality of life. However, recent developments in the regulatory landscape have complicated access to one of the most promising options for CSU patients.

Dupilumab’s Role in CSU Treatment

Dupilumab, marketed under the brand name Dupixent, has been a focal point in the treatment of CSU due to its ability to block specific immune pathways involved in inflammation. Clinical trials have shown that dupilumab can significantly reduce symptoms in patients with CSU. For instance, phase 3 trials reported at week 24 that 30–31% of patients achieved complete response, while 28–32% experienced substantial improvement, according to findings published in peer-reviewed research. These results highlight its potential as a first-line biologic therapy for patients who do not respond to standard antihistamines.

Dupilumab’s mechanism of action involves inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13), cytokines that play a key role in allergic and inflammatory responses. By targeting these pathways, the drug can reduce the frequency and severity of hives, itching, and other associated symptoms like angioedema (swelling beneath the skin). However, its use in CSU has faced regulatory hurdles.

A Setback for CSU Patients

Despite promising clinical data, the U.S. Food and Drug Administration (FDA) rejected Sanofi and Regeneron’s application to expand dupilumab’s approved uses to include chronic spontaneous urticaria in April 2025. This decision came as a setback for patients who had hoped for broader access to the drug, which is already approved for conditions such as atopic dermatitis (eczema), asthma, and chronic rhinosinusitis with nasal polyps. The FDA’s rationale for the rejection has not been publicly detailed, but such decisions often hinge on concerns about efficacy, safety, or the need for additional trial data.

The rejection contrasts with dupilumab’s established role in other inflammatory skin and respiratory conditions. For example, the drug is widely used off-label for CSU in regions where regulatory approval has not been granted, though this practice is not without risks, including potential insurance coverage gaps or lack of formal safety monitoring.

Dermatologist-Approved Remedies for CSU

While dupilumab remains in limbo for CSU, dermatologists continue to recommend a range of evidence-based treatments to manage symptoms. These include:

• Second-generation antihistamines: Drugs like cetirizine, levocetirizine, and fexofenadine are first-line treatments for mild to moderate CSU. Some patients may require higher doses than those approved for allergic rhinitis to achieve symptom control.
• Omalizumab: A monoclonal antibody approved for CSU in patients who do not respond to antihistamines. It works by targeting immunoglobulin E (IgE), a key player in allergic reactions. Clinical trials have shown it can reduce hive frequency and severity in up to 50% of patients.
• Corticosteroids: Oral corticosteroids like prednisone are sometimes used for short-term flare management, though long-term use is discouraged due to side effects such as weight gain, osteoporosis, and increased infection risk.
• Cyclosporine: A calcineurin inhibitor used in refractory CSU cases, particularly when other treatments fail. It suppresses the immune system but carries risks such as kidney toxicity and hypertension.
• Lifestyle and supportive care: Avoiding triggers (e.g., stress, certain foods, heat, or cold), wearing loose clothing, and using cool compresses can help alleviate discomfort. Phototherapy (light therapy) may also be beneficial for some patients.

For patients seeking relief, consulting a dermatologist or allergist is critical. These specialists can tailor treatment plans based on the severity of symptoms, medical history, and response to prior therapies. Emerging research continues to explore new biologics and targeted therapies, offering hope for improved options in the future.

What’s Next for CSU Treatment?

The FDA’s rejection of dupilumab for CSU does not preclude future reconsideration. Sanofi and Regeneron may resubmit their application with additional data or address specific concerns raised by the agency. In the meantime, patients and clinicians must rely on existing therapies while monitoring clinical trials for novel treatments.

Recent years have seen increased interest in biologics and small-molecule inhibitors for CSU, reflecting a broader shift toward precision medicine in dermatology. For example, drugs targeting other immune pathways—such as Bruton’s tyrosine kinase (BTK) inhibitors—are under investigation for their potential to treat refractory CSU. However, these remain experimental and are not yet available outside of clinical trials.

Until new therapies receive regulatory approval, patients with CSU should work closely with their healthcare providers to optimize current treatment strategies. Support groups and patient advocacy organizations can also provide valuable resources, including information on clinical trials and financial assistance programs for approved medications.

As research advances, the landscape for CSU treatment may evolve rapidly. For now, the focus remains on individualized care, evidence-based therapies, and vigilance for emerging opportunities.